IL227952B - Method of diagnosing cancer and diagnosis kit using measurement of nk activity - Google Patents

Method of diagnosing cancer and diagnosis kit using measurement of nk activity

Info

Publication number
IL227952B
IL227952B IL227952A IL22795213A IL227952B IL 227952 B IL227952 B IL 227952B IL 227952 A IL227952 A IL 227952A IL 22795213 A IL22795213 A IL 22795213A IL 227952 B IL227952 B IL 227952B
Authority
IL
Israel
Prior art keywords
measurement
cell activity
diagnostic kit
diagnosing cancer
diagnosing
Prior art date
Application number
IL227952A
Other languages
English (en)
Hebrew (he)
Other versions
IL227952A0 (en
Original Assignee
Atgen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atgen Co Ltd filed Critical Atgen Co Ltd
Publication of IL227952A0 publication Critical patent/IL227952A0/en
Publication of IL227952B publication Critical patent/IL227952B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G01N33/575—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
IL227952A 2011-02-14 2013-08-14 Method of diagnosing cancer and diagnosis kit using measurement of nk activity IL227952B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110012983A KR20120093002A (ko) 2011-02-14 2011-02-14 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
PCT/IB2012/000259 WO2012110878A2 (en) 2011-02-14 2012-02-10 Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity

Publications (2)

Publication Number Publication Date
IL227952A0 IL227952A0 (en) 2013-09-30
IL227952B true IL227952B (en) 2019-01-31

Family

ID=46672988

Family Applications (1)

Application Number Title Priority Date Filing Date
IL227952A IL227952B (en) 2011-02-14 2013-08-14 Method of diagnosing cancer and diagnosis kit using measurement of nk activity

Country Status (20)

Country Link
US (2) US11442069B2 (enExample)
EP (1) EP2676139B1 (enExample)
JP (5) JP6629497B2 (enExample)
KR (3) KR20120093002A (enExample)
CN (1) CN103370622B (enExample)
AU (2) AU2012219184A1 (enExample)
BR (1) BR112013020454B1 (enExample)
CA (1) CA2826053C (enExample)
CL (1) CL2013002361A1 (enExample)
DK (1) DK2676139T3 (enExample)
EA (1) EA038959B1 (enExample)
ES (1) ES2797549T3 (enExample)
IL (1) IL227952B (enExample)
MX (1) MX361731B (enExample)
MY (1) MY175351A (enExample)
RU (1) RU2635194C2 (enExample)
SG (1) SG192247A1 (enExample)
TW (2) TWI681191B (enExample)
UA (1) UA120697C2 (enExample)
WO (1) WO2012110878A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
WO2015069187A1 (en) * 2013-11-05 2015-05-14 Agency For Science, Technology And Research Bladder Carcinoma Biomarkers
JP6073417B2 (ja) * 2015-06-26 2017-02-01 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
KR101926166B1 (ko) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
WO2017204446A2 (ko) * 2016-05-24 2017-11-30 울산대학교 산학협력단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
CN106222140A (zh) * 2016-08-04 2016-12-14 英普乐孚生物技术(上海)有限公司 一种nk细胞无血清培养基及其配制方法
CN107686828A (zh) * 2016-08-04 2018-02-13 英普乐孚生物技术(上海)有限公司 一种nk细胞无血清培养基
CN106085958A (zh) * 2016-08-04 2016-11-09 英普乐孚生物技术(上海)有限公司 一种nk细胞的制备方法
WO2018151821A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
KR102090698B1 (ko) * 2017-08-24 2020-04-23 연세대학교 산학협력단 암의 진단, 모니터링, 또는 예후 예측을 위해 생체 외 인터페론-감마의 양을 측정하는 방법
CA3089853A1 (en) 2018-02-01 2019-08-08 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
US20220128564A1 (en) * 2019-02-14 2022-04-28 Research Institute At Nationwide Children's Hospital Use of a stimulating agent to assay immune cell potency
EP4021180A4 (en) * 2019-08-29 2023-11-08 Board of Regents, The University of Texas System CELL CRYOPRESERVATION MEDIUM
EP4015526B1 (en) * 2019-09-25 2024-10-30 Leto Laboratories Co., Ltd Recombinant interleukin-15 analog
CN114929249A (zh) * 2019-11-29 2022-08-19 Nkmax有限公司 产生自然杀伤细胞及其组合物的方法
CN113533729B (zh) * 2021-06-15 2024-09-06 北京大学人民医院 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用
CN118488963A (zh) * 2021-12-17 2024-08-13 肯特大学 囊泡中生产重组生物分子的序列和方法
KR20230156518A (ko) 2022-05-06 2023-11-14 (주)다이오진 엑소좀 내의 인터페론 감마 유전자 측정을 이용한 암 조기 진단 방법 및 진단 키트
CN115247149B (zh) * 2022-08-22 2023-06-16 华域生物科技(天津)有限公司 适用于nk细胞的培养基组合物及培养方法
CN115855779A (zh) * 2023-01-18 2023-03-28 山东康华生物医疗科技股份有限公司 一种定量检测nk细胞活性的磁微粒化学发光试剂盒及其检测方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT89121A (pt) * 1987-12-04 1989-12-29 Du Pont Processo para a preparacao de interleuquina-2 imobilizada e interleuquina-2 contendo uma extensao no terminal-carboxilo com actividade de interleuquina-2 natural
AU693459B2 (en) * 1993-08-09 1998-07-02 Edward Baral A method for sensitization of cancer cells for killer cell mediated lysis
DE69620877T2 (de) * 1995-02-06 2002-12-12 Genetics Institute, Inc. Arzneimittelformulierungen für il-12
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
JP3995248B2 (ja) * 2001-08-13 2007-10-24 準二郎 土山 エプスタインバーウイルス陰性のｎｋ細胞株
EP1451217A4 (en) * 2001-11-20 2005-10-12 Atgen Co Ltd NEW PEPTIDES PROVIDING ENVIRONMENTAL RESISTANCE, AND FUSION PROTEINS CONTAINING THOSE PEPTIDES
WO2003082206A2 (en) * 2002-03-26 2003-10-09 Centocor, Inc. Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
JP2004305095A (ja) 2003-04-07 2004-11-04 Limuloid Science Kk 細胞活性化検出方法
CN1297567C (zh) * 2003-06-13 2007-01-31 马菁 具有抗肿瘤功能的双功能融合蛋白及其制备方法和应用
EP1925626A1 (en) * 2003-07-21 2008-05-28 Transgene S.A. Novel multifunctional cytokines
WO2005013950A2 (en) 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
AU2004288231A1 (en) 2003-11-05 2005-05-19 Palingen, Inc. Enhanced B cell cytotoxicity of CDIM binding antibody
KR100565764B1 (ko) * 2005-05-02 2006-03-28 (주)에이티젠 환경 스트레스에 내성을 부여하는 신규한 펩타이드 및 이를포함하는 융합 단백질
US20050203010A1 (en) * 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
JP4653465B2 (ja) 2004-10-25 2011-03-16 泰信 小林 ナチュラルキラー細胞の増殖促進方法およびそれに用いる培養組成物
CA2604007A1 (en) * 2005-04-08 2006-10-19 Morningside Venture Investments Limited Use of fril proteins for reducing the production of pro-inflammatory cytokines
AU2007277050A1 (en) * 2006-07-28 2008-01-31 The Research Foundation Of State University Of New York Methods and kits for measurement of lymphocyte function
WO2008070647A1 (en) * 2006-12-07 2008-06-12 Wyeth Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
ES2579768T3 (es) 2007-01-11 2016-08-16 Novo Nordisk A/S Anticuerpos anti-KIR, formulaciones y usos de los mismos
EP2048237A1 (en) * 2007-10-05 2009-04-15 Avir Green Hills Biotechnology Research Development Trade Ag Replication deficient Influenza virus for the expression of heterologous sequences
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트

Also Published As

Publication number Publication date
MY175351A (en) 2020-06-22
WO2012110878A3 (en) 2013-01-31
RU2635194C2 (ru) 2017-11-09
TWI681191B (zh) 2020-01-01
IL227952A0 (en) 2013-09-30
MX361731B (es) 2018-12-14
US20220229070A1 (en) 2022-07-21
KR20120093002A (ko) 2012-08-22
KR20130032410A (ko) 2013-04-01
TW201245718A (en) 2012-11-16
WO2012110878A2 (en) 2012-08-23
JP2022043119A (ja) 2022-03-15
JP6629497B2 (ja) 2020-01-15
ES2797549T3 (es) 2020-12-02
US20140017713A1 (en) 2014-01-16
US12379384B2 (en) 2025-08-05
EP2676139A2 (en) 2013-12-25
JP2014510517A (ja) 2014-05-01
EA038959B1 (ru) 2021-11-15
JP2017129597A (ja) 2017-07-27
KR101438573B1 (ko) 2014-09-12
EP2676139B1 (en) 2020-05-06
KR101341538B1 (ko) 2013-12-18
BR112013020454A8 (pt) 2022-11-29
AU2017202628A1 (en) 2017-05-11
BR112013020454B1 (pt) 2023-03-21
JP6798922B2 (ja) 2020-12-09
TWI668445B (zh) 2019-08-11
JP2023115006A (ja) 2023-08-18
EP2676139A4 (en) 2014-12-03
NZ710432A (en) 2017-04-28
JP7660605B2 (ja) 2025-04-11
AU2017202628B2 (en) 2019-08-22
BR112013020454A2 (pt) 2016-10-18
RU2013141487A (ru) 2015-03-27
NZ614345A (en) 2015-09-25
DK2676139T3 (da) 2020-06-15
MX2013009380A (es) 2013-12-16
EA201391187A1 (ru) 2013-12-30
AU2012219184A1 (en) 2013-09-05
KR20130136012A (ko) 2013-12-11
CN103370622B (zh) 2018-02-13
TW201741670A (zh) 2017-12-01
CA2826053A1 (en) 2012-08-23
CA2826053C (en) 2021-05-25
CN103370622A (zh) 2013-10-23
US11442069B2 (en) 2022-09-13
JP2019207242A (ja) 2019-12-05
CL2013002361A1 (es) 2014-06-27
SG192247A1 (en) 2013-09-30
UA120697C2 (uk) 2020-01-27

Similar Documents

Publication Publication Date Title
IL227952B (en) Method of diagnosing cancer and diagnosis kit using measurement of nk activity
IL264770B (en) Diagnostic assays and kits for detection of folate receptor 1
PT2710375T (pt) Ensaios de atividade dependente de modificação
IL232119B (en) Fetal chromosomal aneuploidy diagnosis
DK2649468T3 (da) Ultralydsmåling
IL223147B (en) Means and methods for diagnosing pancreatic cancer in a subject
EP2637680A4 (en) CANCER THERAPIES AND DIAGNOSTICS
SG11201406561XA (en) Test probe assembly and related methods
SG11201401110WA (en) Methods and systems for measuring and using the oxidation-reduction potential of a biological sample
DK2624757T3 (da) Diagnoseindretning
EP2758933A4 (en) CLINICAL ANALYSIS USING ELECTRODERMIC ACTIVITY
EP2871470A4 (en) ELECTROCHEMICAL BIOSENSOR WITH IMPROVED ACCURACY
GB201410773D0 (en) Test device for electrochemical analysis
BR112013015362A2 (pt) ferramenta de intervenção e de diagnóstico de meningite para despacho de emergência
EP2813184A4 (en) ULTRASONIC PROBE AND MANUFACTURING METHOD THEREOF
EP2707710A4 (en) CANCER DIAGNOSIS
EP2936206A4 (en) ERROR REDUCTION IN GNSS-PSEUDOREICHWAY MEASUREMENTS
DE112011101867B8 (de) Fahrzeugfunktionsprüfstand
EP2565682A4 (en) NEUTRON SCINTILLATOR AND NEUTRON DETECTOR
IL230693A0 (en) Use of the i-3859 antibody for the detection and diagnosis of cancer
EP2527004A4 (en) ULTRASONIC PROBE
EP2569451A4 (en) METHOD AND DEVICES FOR DIAGNOSING MORBUS ALZHEIMER
DE102011013002B8 (de) Durchströmbare Messzelle
IL232642A0 (en) Method for characterizing circulating tumor cells, and use thereof in diagnosis
GB201119005D0 (en) Ultrasound probe

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed